September 2015

EMD Serono appoints U.S. CMO

Wednesday, September 30, 2015

EMD Serono, the U.S. biopharmaceutical business of Germany-based Merck, has appointed Joseph Leveque, M.D., as U.S. chief medical officer. Leveque will be responsible for working with the regulatory, medical and development teams to enhance EMD Serono’s clinical presence in the U.S. and to drive the execution of crucial medical initiatives.

[Read More]

Protectimmun partners with J&J, Imperial College

Wednesday, September 30, 2015

Protectimmun, a Germany-based biopharmaceutical R&D company, has entered into a research funding agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and Imperial College London. The research agreement, facilitated by Johnson & Johnson Innovation, will fund preclinical research conducted at Imperial College by professor Clare Lloyd with one of Protectimmun’s lead candidates in a proof-of-concept disease model of allergic asthma developed by Lloyd.

[Read More]

Martindale Pharma expands in Saudi Arabia

Wednesday, September 30, 2015

Martindale Pharma, a U.K.-based international specialty pharmaceutical company, has opened a scientific office in the Kingdom of Saudi Arabia (KSA) and has appointed Dr. Fahad Al Showaier as scientific office manager. He brings extensive international experience, having previously held a number of senior positions with Saudi companies including Jamjoom Pharma.

[Read More]

Symbiodx, Cure Forward partner on precision medicine

Wednesday, September 30, 2015

Symbiodx, a molecular reference laboratory in the Pacific Northwest, and Cure Forward, a Cambridge, Mass.-based, multisided technology platform to support patient engagement, are collaborating to advance precision medicine. The partnership will provide patients with streamlined access to their genomic data and greater exposure to relevant clinical trials.

[Read More]

WCG, PCCTC partner to improve oncology research reviews

Tuesday, September 29, 2015

WIRB-Copernicus Group (WCG), a provider of regulatory and ethical review services and software to support clinical research, and the Prostate Cancer Clinical Trials Consortium (PCCTC), a multicenter clinical research organization specializing in cutting-edge prostate cancer research, have formed a new partnership to enhance the quality and efficiency of the consortium’s research review process.

[Read More]

ProPhase, YPrime team to develop eCOA, other digital products

Tuesday, September 29, 2015

New York-based ProPhase, a global provider of measurement expertise in clinical trials, and Malvern, Pa.-based YPrime, a clinical trial software products and services company, have formed a strategic partnership to develop digital products that create new clinical trial standardization processes and tools, from trial design and patient selection to using data analytics to improve endpoints and study results.

[Read More]

NIH launches substance use and adolescent brain development study

Monday, September 28, 2015

The NIH has awarded 13 grants to research institutions around the country as part of a study about the effects of adolescent substance use on the developing brain. The Adolescent Brain Cognitive Development (ABCD) Study will follow about 10,000 children beginning at ages 9 and 10, before they initiate drug use, through the period of highest risk for substance use and other mental health disorders. Scientists will track exposure to substances (including nicotine, alcohol and marijuana), academic achievement, cognitive skills, mental health and brain structure and function using advanced research methods.

[Read More]